| Literature DB >> 26221519 |
Chizumi Yamada1, Masumi Kondo1, Noriaki Kishimoto1, Takeo Shibata2, Yoko Nagai2, Tadashi Imanishi2, Takashige Oroguchi3, Naoaki Ishii4, Yasuhiro Nishizaki5.
Abstract
AIMS/Entities:
Keywords: Amino acids; Homeostasis model assessment of insulin resistance; Insulin resistance
Year: 2015 PMID: 26221519 PMCID: PMC4511300 DOI: 10.1111/jdi.12323
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Background characteristics of the study participants
| All | Men | Women | |
|---|---|---|---|
| No. participants | 94 | 48 | 46 |
| Age (years) | 40.1 ± 9.6 | 42.0 ± 10.2 | 38.1 ± 8.6 |
| Bodyweight (kg) | 63.2 ± 14.5 | 72.5 ± 12.4 | 53.4 ± 9.3 |
| BMI (kg/m2) | 22.7 ± 3.9 | 24.1 ± 3.8 | 21.2 ± 3.5 |
| Waist circumference (cm) | 80.4 ± 10.6 | 85.4 ± 9.9 | 75.2 ± 8.7 |
| Visceral fat (cm2) | 47.4 ± 40.9 | 70.5 ± 41.4 | 23.3 ± 22.3 |
| Subcutaneous fat (cm2) | 136.3 ± 80.8 | 139.4 ± 90.2 | 133.0 ± 70.4 |
| Body fat mass (kg) | 15.6 ± 7.4 | 16.4 ± 8.3 | 14.8 ± 6.4 |
| Fat free mass (kg) | 44.9 ± 9.7 | 53.0 ± 5.5 | 36.3 ± 4.2 |
| %Body fat (%) | 24.3 ± 7.5 | 21.8 ± 7.0 | 26.9 ± 7.1 |
| Systolic BP (mmHg) | 119.6 ± 15.2 | 124.8 ± 12.2 | 114.1 ± 16.1 |
| Diastolic BP (mmHg) | 77.6 ± 13.2 | 82.5 ± 11.7 | 72.4 ± 12.8 |
| Fasting glucose (mg/dL) | 89.8 ± 8.7 | 93.2 ± 9.2 | 86.3 ± 6.7 |
| HbA1c (%) | 5.3 ± 0.3 | 5.3 ± 0.3 | 5.3 ± 0.3 |
| Fasting insulin (μU/mL) | 4.97 ± 2.92 | 5.69 ± 3.41 | 4.21 ± 2.06 |
| HOMA-IR | 1.12 ± 0.72 | 1.33 ± 0.85 | 0.90 ± 0.46 |
| LDL-C (mg/dL) | 113.5 ± 32.2 | 120.2 ± 31.4 | 106.5 ± 31.9 |
| HDL-C (mg/dL) | 65.1 ± 16.8 | 57.3 ± 13.2 | 73.2 ± 16.4 |
| Triglyceride (mg/dL) | 107.7 ± 84.0 | 134.7 ± 99.6 | 79.5 ± 51.4 |
| AST (U/L) | 20.6 ± 5.6 | 22.9 ± 5.7 | 18.3 ± 4.5 |
| ALT (U/L) | 19.9 ± 12.4 | 25.6 ± 14.0 | 14.0 ± 6.5 |
| γGT (U/L) | 33.5 ± 30.7 | 45.9 ± 37.4 | 20.5 ± 12.0 |
| Uric acid (mg/dL) | 5.3 ± 1.3 | 6.1 ± 1.1 | 4.5 ± 0.9 |
| Leptin (ng/mL) | 7.92 ± 6.24 | 5.46 ± 3.78 | 10.49 ± 7.23 |
| Adiponectin (μg/mL) | 3.65 ± 2.46 | 2.28 ± 1.30 | 5.08 ± 2.58 |
| hsCRP (ng/mL) | 1055.3 ± 4929.6 | 1564.3 ± 6792.4 | 524.2 ± 1212.2 |
Data are mean ± SD.
γGT, γ-glutamyl transpeptidase
ALT, alanine aminotransferase
AST, aspartate aminotransferase
BMI, body mass index
BP, blood pressure
HbA1c, glycated hemoglobin
HDL-C, high-density lipoprotein cholesterol
HOMA-IR, homeostasis model assessment of insulin resistance
hsCRP, high-sensitivity C-reactive protein
LDL-C, low-density lipoprotein cholesterol.
Average amino acid concentrations
| (nmol/mL) | All | Men | Women |
|---|---|---|---|
| Glycine | 209 ± 50.3 | 213.1 ± 43.9 | 206.0 ± 56.5 |
| Alanine | 329.0 ± 62.3 | 355.7 ± 59.0 | 301.2 ± 53.4 |
| Serine | 112.7 ± 20.3 | 109.6 ± 19.9 | 115.9 ± 20.3 |
| Threonine | 123.5 ± 24.7 | 123.2 ± 19.4 | 123.7 ± 29.5 |
| Valine | 206.7 ± 37.8 | 229.0 ± 29.1 | 183.3 ± 31.3 |
| Isoleucine | 59.6 ± 12.8 | 68.0 ± 10.6 | 50.9 ± 8.2 |
| Leucine | 118.3 ± 23.6 | 135.6 ± 15.5 | 100.3 ± 15.7 |
| Lysine | 172.0 ± 31.6 | 189.8 ± 25.1 | 153.4 ± 26.8 |
| Arginine | 51.0 ± 16.8 | 51.9 ± 15.8 | 50.1 ± 17.9 |
| Histidine | 78.9 ± 8.1 | 83.2 ± 7.3 | 74.4 ± 6.3 |
| Tyrosine | 57.7 ± 10.4 | 62.0 ± 9.2 | 53.2 ± 9.8 |
| Phenylalanine | 55.1 ± 8.4 | 59.8 ± 7.6 | 50.2 ± 6.1 |
| Tryptophan | 55.7 ± 8.8 | 59.6 ± 8.7 | 51.7 ± 7.1 |
| Methionine | 23.4 ± 4.0 | 25.1 ± 3.6 | 21.6 ± 3.7 |
| Cysteine | 12.7 ± 4.1 | 13.8 ± 4.4 | 11.5 ± 3.4 |
| Proline | 137.2 ± 39.7 | 157.6 ± 40.0 | 115.8 ± 26.0 |
| Glutamine | 507.2 ± 70.9 | 539.0 ± 58.5 | 474.0 ± 67.9 |
| Glutamic acid | 40.7 ± 18.4 | 50.2 ± 18.0 | 30.9 ± 13.0 |
| Asparagine | 47.0 ± 6.9 | 48.5 ± 7.4 | 45.5 ± 6.1 |
| Aspartic acid | 2.9 ± 0.8 | 3.0 ± 1.0 | 2.7 ± 0.5 |
| Total AA | 2570.7 ± 298.1 | 2759.4 ± 191.4 | 2373.7 ± 260.2 |
| NEAA | 1677.5 ± 209.6 | 1786.2 ± 148.3 | 1564.1 ± 205.0 |
| EAA | 893.1 ± 121.0 | 973.2 ± 83.2 | 809.6 ± 95.2 |
| BCAA | 384.6 ± 71.0 | 432.6 ± 50.8 | 334.5 ± 52.0 |
Data are mean ± SD.
BCAA, branched-chain amino acid
EAA, essential amino acid
NEAA, non-essential amino acid; Total AA, total amino acid.
Correlations between homeostasis model assessment of insulin resistance and clinical parameters
| All | Men | Women | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Age | 0.045 | 0.667 | 0.013 | 0.930 | −0.084 | 0.580 |
| Bodyweight | 0.471 | <0.001 | 0.326 | 0.024 | 0.547 | <0.001 |
| BMI | 0.511 | <0.001 | 0.393 | 0.006 | 0.612 | <0.001 |
| Waist circumference | 0.542 | <0.001 | 0.479 | 0.001 | 0.510 | <0.001 |
| Visceral fat | 0.626 | <0.001 | 0.627 | <0.001 | 0.430 | 0.003 |
| Subcutaneous fat | 0.374 | <0.001 | 0.307 | 0.034 | 0.576 | <0.001 |
| Body fat mass | 0.509 | <0.001 | 0.478 | 0.001 | 0.585 | <0.001 |
| Fat free mass | 0.299 | 0.003 | 0.006 | 0.968 | 0.301 | 0.042 |
| %Body fat | 0.374 | <0.001 | 0.565 | <0.001 | 0.534 | <0.001 |
| Systolic BP | 0.410 | <0.001 | 0.412 | 0.004 | 0.318 | 0.031 |
| Diastolic BP | 0.391 | <0.001 | 0.357 | 0.013 | 0.289 | 0.051 |
| Fasting glucose | 0.435 | <0.001 | 0.388 | 0.006 | 0.303 | 0.041 |
| HbA1c | 0.194 | 0.060 | 0.137 | 0.354 | 0.263 | 0.077 |
| Fasting insulin | 0.985 | <0.001 | 0.985 | <0.001 | 0.989 | <0.001 |
| LDL-C | 0.132 | 0.206 | 0.096 | 0.514 | 0.038 | 0.802 |
| HDL-C | −0.485 | <0.001 | −0.344 | 0.017 | −0.597 | <0.001 |
| Triglyceride | 0.595 | <0.001 | 0.618 | <0.001 | 0.303 | 0.041 |
| AST | 0.348 | 0.001 | 0.231 | 0.113 | 0.340 | 0.021 |
| ALT | 0.482 | <0.001 | 0.365 | 0.011 | 0.586 | <0.001 |
| γGT | 0.408 | <0.001 | 0.381 | 0.008 | 0.048 | 0.750 |
| Uric acid | 0.319 | 0.002 | 0.348 | 0.015 | −0.199 | 0.184 |
| Leptin | 0.392 | <0.001 | 0.621 | <0.001 | 0.792 | <0.001 |
| Adiponectin | −0.336 | 0.001 | −0.305 | 0.035 | −0.213 | 0.155 |
| hsCRP | 0.296 | 0.004 | 0.286 | 0.049 | 0.375 | 0.010 |
γGT, γ-glutamyl transpeptidase
ALT, alanine aminotransferase
AST, aspartate aminotransferase
BMI, body mass index
BP, blood pressure
HbA1c, glycated hemoglobin
HDL-C, high-density lipoprotein cholesterol
hsCRP, high-sensitivity C-reactive protein
LDL-C, low-density lipoprotein cholesterol.
Correlations between homeostasis model assessment of insulin resistance and plasma amino acid levels
| All | Men | Women | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Glycine | −0.120 | 0.248 | −0.326 | 0.024 | 0.084 | 0.578 |
| Alanine | 0.439 | <0.001 | 0.478 | 0.001 | 0.140 | 0.354 |
| Serine | −0.231 | 0.025 | −0.374 | 0.009 | 0.114 | 0.451 |
| Threonine | −0.113 | 0.276 | −0.222 | 0.129 | −0.016 | 0.918 |
| Valine | 0.384 | <0.001 | 0.245 | 0.094 | 0.354 | 0.016 |
| Isoleucine | 0.495 | <0.001 | 0.385 | 0.007 | 0.520 | <0.001 |
| Leucine | 0.430 | <0.001 | 0.323 | 0.025 | 0.383 | 0.009 |
| Lysine | 0.153 | 0.141 | −0.017 | 0.908 | −0.040 | 0.792 |
| Arginine | 0.192 | 0.063 | 0.265 | 0.068 | 0.079 | 0.600 |
| Histidine | 0.294 | 0.004 | 0.152 | 0.301 | 0.209 | 0.164 |
| Tyrosine | 0.462 | <0.001 | 0.462 | 0.001 | 0.313 | 0.034 |
| Phenylalanine | 0.398 | <0.001 | 0.292 | 0.044 | 0.304 | 0.040 |
| Tryptophan | 0.153 | 0.141 | −0.021 | 0.886 | 0.132 | 0.383 |
| Methionine | 0.157 | 0.131 | 0.026 | 0.862 | 0.058 | 0.704 |
| Cysteine | 0.204 | 0.049 | 0.151 | 0.305 | 0.088 | 0.563 |
| Proline | 0.396 | <0.001 | 0.312 | 0.031 | 0.249 | 0.095 |
| Glutamine | 0.075 | 0.474 | −0.154 | 0.297 | 0.047 | 0.758 |
| Glutamic acid | 0.461 | <0.001 | 0.448 | 0.001 | 0.195 | 0.195 |
| Asparagine | −0.184 | 0.077 | −0.229 | 0.117 | −0.370 | 0.011 |
| Aspartic acid | 0.400 | <0.001 | 0.383 | 0.011 | 0.303 | 0.087 |
| Total AA | 0.324 | 0.001 | 0.202 | 0.168 | 0.194 | 0.197 |
| NEAA | 0.266 | 0.010 | 0.162 | 0.271 | 0.128 | 0.396 |
| EAA | 0.336 | 0.001 | 0.176 | 0.230 | 0.254 | 0.089 |
| BCAA | 0.436 | <0.001 | 0.319 | 0.027 | 0.410 | 0.005 |
BCAA, branched-chain amino acid
EAA, essential amino acid
NEAA, non-essential amino acid
Total AA, total amino acid.
Figure 1Correlation between homeostasis model assessment of insulin resistance (HOMA-IR) and branched-chain amino acids (BCAAs) and aromatic amino acids. Significant correlations were observed (P < 0.01) between HOMA-IR and valine, isoleucine, leucine, tyrosine, phenylalanine and BCAA. Correlation diagrams for the whole population are shown.
Comparison of clinical parameters between homeostasis model assessment of insulin resistance ≤1.6 and homeostasis model assessment of insulin resistance >1.6 groups
| HOMA-IR ≤ 1.6 | HOMA-IR > 1.6 |
| |
|---|---|---|---|
| No. men/women | 38 (47%)/42 (53%) | 10 (71%)/4 (29%) | 0.086 |
| Age (years) | 40.5 ± 9.7 | 37.9 ± 9.1 | 0.360 |
| Body weight (kg) | 60.5 ± 11.9 | 78.6 ± 18.7 | <0.001 |
| BMI (kg/m2) | 21.8 ± 2.9 | 27.5 ± 5.1 | <0.001 |
| Waist circumference (cm) | 78.1 ± 8.2 | 93.2 ± 13.6 | <0.001 |
| Visceral fat (cm2) | 39.2 ± 33.1 | 94.4 ± 50.1 | <0.001 |
| Subcutaneous fat (cm2) | 121.1 ± 57.7 | 222.9 ± 130.3 | <0.001 |
| Body fat mass (kg) | 14.0 ± 5.2 | 25.1 ± 10.8 | <0.001 |
| Fat free mass (kg) | 43.9 ± 9.3 | 50.5 ± 10.2 | 0.017 |
| %Body fat (%) | 23.1 ± 6.8 | 31.2 ± 7.7 | <0.001 |
| Systolic BP (mmHg) | 117.4 ± 14.4 | 131.9 ± 13.7 | 0.001 |
| Diastolic BP (mmHg) | 75.8 ± 11.8 | 87.9 ± 16.2 | 0.001 |
| Fasting glucose (mg/dL) | 88.7 ± 8.1 | 96.2 ± 9.6 | 0.003 |
| HbA1c (%) | 5.29 ± 0.26 | 5.40 ± 0.33 | 0.164 |
| Fasting insulin (μU/mL) | 4.08 ± 1.47 | 10.00 ± 3.94 | <0.001 |
| HOMA-IR | 0.90 ± 0.34 | 2.38 ± 0.98 | <0.001 |
| LDL-C (mg/dL) | 111.8 ± 31.9 | 123.1 ± 33.5 | 0.226 |
| HDL-C (mg/dL) | 67.4 ± 16.7 | 51.9 ± 9.5 | 0.001 |
| Triglyceride (mg/dL) | 95.8 ± 65.9 | 175.4 ± 135.3 | 0.001 |
| AST (U/L) | 19.9 ± 5.0 | 25.0 ± 7.1 | 0.001 |
| ALT (U/L) | 17.9 ± 9.4 | 31.5 ± 19.8 | <0.001 |
| γGT (U/L) | 29.2 ± 26.6 | 57.9 ± 40.8 | 0.001 |
| Uric acid (mg/dL) | 5.2 ± 1.2 | 5.9 ± 1.5 | 0.074 |
| Leptin (ng/mL) | 6.64 ± 4.13 | 15.25 ± 10.36 | <0.001 |
| Adiponectin (μg/mL) | 3.90 ± 2.49 | 2.23 ± 1.78 | 0.019 |
| hsCRP (ng/mL) | 461.6 ± 945.2 | 4448.3 ± 12403.6 | 0.005 |
Data are mean ± SD, unless otherwise stated.
γGT, γ-glutamyl transpeptidase
ALT, alanine aminotransferase
AST, aspartate aminotransferase
BMI, body mass index
BP, blood pressure
HbA1c, glycated hemoglobin
HDL-C, high-density lipoprotein cholesterol
HOMA-IR, homeostasis model assessment of insulin resistance
hsCRP, high-sensitivity C-reactive protein
LDL-C, low-density lipoprotein cholesterol.
Comparison of amino acid profile by insulin resistance
| (nmol/mL) | HOMA-IR ≤ 1.6 | HOMA-IR > 1.6 |
|
|---|---|---|---|
| Glycine | 211.1 ± 51.7 | 201.1 ± 42.4 | 0.495 |
| Alanine | 321.8 ± 58.3 | 370.2 ± 70.8 | 0.007 |
| Serine | 114.2 ± 20.2 | 104.3 ± 19.1 | 0.092 |
| Threonine | 123.9 ± 26.2 | 120.8 ± 14.2 | 0.662 |
| Valine | 202.2 ± 36.8 | 232.0 ± 34.3 | 0.006 |
| Isoleucine | 57.5 ± 11.3 | 72.0 ± 14.0 | <0.001 |
| Leucine | 115.2 ± 22.6 | 135.7 ± 22.0 | 0.002 |
| Lysine | 171.4 ± 31.9 | 175.1 ± 30.9 | 0.695 |
| Arginine | 49.4 ± 16.6 | 60.2 ± 15.8 | 0.027 |
| Histidine | 78.3 ± 8.1 | 82.7 ± 6.9 | 0.060 |
| Tyrosine | 56.2 ± 10.0 | 66.0 ± 8.9 | 0.001 |
| Phenylalanine | 53.9 ± 8.1 | 61.6 ± 7.2 | 0.001 |
| Tryptophan | 55.3 ± 8.4 | 58.2 ± 10.8 | 0.256 |
| Methionine | 23.2 ± 4.1 | 24.2 ± 3.8 | 0.418 |
| Cysteine | 12.5 ± 4.1 | 13.8 ± 3.6 | 0.272 |
| Proline | 131.9 ± 34.4 | 167.2 ± 54.3 | 0.002 |
| Glutamine | 505.6 ± 72.7 | 515.9 ± 61.2 | 0.619 |
| Glutamic acid | 38.5 ± 16.2 | 53.6 ± 25.1 | 0.004 |
| Asparagine | 47.6 ± 6.6 | 43.8 ± 7.7 | 0.057 |
| Aspartic acid | 2.8 ± 0.6 | 3.4 ± 1.4 | 0.014 |
| Total AA | 2544.0 ± 299.2 | 2723.1 ± 249.6 | 0.037 |
| NEAA | 1663.0 ± 211.7 | 1760.9 ± 182.1 | 0.107 |
| EAA | 881.0 ± 120.1 | 962.1 ± 105.4 | 0.020 |
| BCAA | 374.9 ± 67.7 | 439.7 ± 66.6 | 0.001 |
Data are mean ± SD.
BCAA, branched-chain amino acid
EAA, essential amino acid
HOMA-IR, homeostasis model assessment of insulin resistance
NEAA, non-essential amino acid
Total AA, total amino acid.